Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Core Insights - Illumina reported a strong financial performance for Q4 2025, with revenue of $1.16 billion, up 5% from Q4 2024, and a GAAP diluted EPS of $2.16 [1][3] - The company achieved a GAAP operating margin of 17.4% and a non-GAAP operating margin of 23.7% for Q4 2025, indicating improved operational efficiency [1][4] - For fiscal year 2025, total revenue was $4.34 billion, flat compared to 2024, with a GAAP diluted EPS of $5.45 [1][3] Financial Performance - Q4 2025 results showed a gross margin of 65.5% (GAAP) and 67.0% (non-GAAP), with operating profit of $202 million [1][4] - Fiscal year 2025 saw a net income of $850 million, with a GAAP tax provision of $236 million and a tax rate of 21.7% [1][4] - Free cash flow for Q4 2025 was $267 million, down from $322 million in the prior year [1][3] Revenue Breakdown - Ex-China revenue for Q4 2025 was $1.10 billion, up 8% from Q4 2024 [1][3] - The company expects total revenue for fiscal year 2026 to be between $4.5 billion and $4.6 billion, representing growth of 4% to 6% [1][4] - Organic revenue growth (excluding currency and acquisition impacts) is projected to be 2% to 4% for fiscal year 2026 [1][4] Strategic Developments - Illumina completed the acquisition of SomaLogic, enhancing its multiomics portfolio and positioning in NGS-enabled proteomics [1][6] - The company appointed Eric Green, MD, PhD, as Chief Medical Officer to advance clinical genomics [1][6] - Progress was made in China with the lifting of the export ban on Illumina sequencers, although the company remains on the Unreliable Entities List [1][4] Market Outlook - The CEO expressed confidence in the company's growth momentum, particularly in clinical markets where NGS-based testing adoption is increasing [1][4] - The company is focusing on innovation in DNA sequencing and array-based technologies to improve human health [1][6]